Nystatin Oral Solution: Clinical Indications
Nystatin oral suspension is indicated for the treatment of oral candidiasis (thrush), serving as an alternative topical agent for mild oropharyngeal candidiasis when first-line therapies are not suitable. 1
Primary Clinical Use
Oropharyngeal Candidiasis (Oral Thrush)
For mild oropharyngeal candidiasis, nystatin suspension (100,000 U/mL) at 4–6 mL four times daily for 7–14 days is recommended as an alternative to clotrimazole troches or miconazole buccal tablets. 2 This represents a strong recommendation with moderate-quality evidence from the 2016 IDSA guidelines.
- Dosing specifics: Nystatin pastilles (200,000 U each) can also be used at 1–2 pastilles four times daily for the same duration 2
- Position in treatment hierarchy: Nystatin is positioned as an alternative rather than first-line therapy; clotrimazole troches and miconazole buccal tablets are preferred for mild disease based on higher quality evidence 2
Important Clinical Context
Nystatin is NOT appropriate for moderate-to-severe oropharyngeal candidiasis or esophageal candidiasis—these require systemic therapy with fluconazole. 2 The drug acts only topically as gastrointestinal absorption is insignificant, with most passing unchanged in stool 1.
Neonatal Prophylaxis (Special Population)
In neonatal intensive care units, oral nystatin (1 mL of 100,000 IU every 8 hours) can reduce fungal colonization and invasive candidiasis in extremely low birth weight (<1000g) infants, though it does not reduce mortality. 3, 4 This carries a B-II recommendation (moderate evidence, generally recommended).
Critical caveat: There are concerns about potential gut damage and necrotizing enterocolitis with nystatin prophylaxis in neonates 3. Fluconazole prophylaxis has stronger evidence in high-risk NICUs.
Mechanism and Limitations
Nystatin binds to sterols in Candida cell membranes, causing leakage of intracellular components 1. It is both fungistatic and fungicidal against Candida species, though some non-albicans species can develop resistance 1.
Key Limitations in Practice
- Efficacy concerns: Studies show nystatin has inferior cure rates compared to fluconazole for oral thrush (32% vs 100% in one pediatric study) 5
- Compliance issues: Four-times-daily dosing is burdensome compared to once-daily fluconazole
- Formulation concerns: Many commercial preparations contain sugar (cariogenic risk) and ethanol, which may be problematic in certain populations 6
- No systemic activity: Cannot treat esophageal extension or systemic candidiasis 1
When to Choose Nystatin
Use nystatin oral suspension when:
- Patient has mild oropharyngeal candidiasis only (no esophageal involvement)
- Systemic azoles are contraindicated or unavailable
- Cost is a significant barrier (nystatin is generally less expensive)
- Patient preference for topical over systemic therapy exists
Do NOT use nystatin for:
- Moderate-to-severe oropharyngeal candidiasis (use fluconazole 100-200 mg daily) 2
- Esophageal candidiasis (requires systemic fluconazole 200-400 mg daily) 2
- Fluconazole-refractory disease (requires itraconazole, posaconazole, or echinocandins) 2
- Immunocompromised patients with significant disease burden
Adverse Effects
Nystatin is generally well-tolerated. Reported adverse effects include oral irritation, gastrointestinal upset, diarrhea (rarely bloody), nausea, and rare hypersensitivity reactions including rash and Stevens-Johnson syndrome 1.
Special Considerations for Denture Wearers
For denture-related candidiasis, disinfection of the denture in addition to antifungal therapy is mandatory for treatment success. 2 Nystatin alone without denture hygiene will result in treatment failure.